Kalvista Pharm Stock Price, News & Analysis

KalVista Pharmaceuticals (NASDAQ: KALV) has granted inducement options to nine newly-hired employees. The options allow for the purchase of a total of 55,000 shares of KalVista common stock at an exercise price of $12.37 per share, matching the closing price on September 3, 2024. These options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. The grants, made under KalVista's Inducement Equity Incentive Plan, are subject to continued employment and have a 10-year term. This action aligns with Nasdaq Listing Rule 5635(c)(4), which allows for inducement grants to new employees.

KalVista Pharmaceuticals (NASDAQ: KALV) announced FDA acceptance of its New Drug Application (NDA) for sebetralstat, an oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema (HAE) attacks. The FDA set a PDUFA goal date of June 17, 2025. If approved, sebetralstat would be the first oral, on-demand treatment for HAE in patients aged 12 and older.

The NDA is supported by data from the KONFIDENT phase 3 trial and ongoing KONFIDENT-S open label extension trial. Sebetralstat met the primary endpoint, achieving faster symptom relief than placebo and demonstrating a favorable safety profile. The KONFIDENT-KID trial for pediatric patients aged 2-11 years has begun dosing. KalVista has also submitted a Marketing Authorization Application to the European Medicines Agency and plans to file for approval in other countries in 2024.

KalVista Pharmaceuticals (NASDAQ: KALV) announced the acceptance of six abstracts for presentation at the 2024 Bradykinin Symposium in Berlin, Germany. The event, scheduled for September 5-6, 2024, will feature four oral presentations and two poster presentations on Friday, September 6.

The presentations cover various aspects of sebetralstat, KalVista's drug for Hereditary Angioedema (HAE) treatment. Topics include delayed on-demand treatment, pooled safety and efficacy data, a specific assay for measuring plasma kallikrein activity, and interim analysis of the KONFIDENT-S study. The European subgroup results from the Phase 3 KONFIDENT trial will also be presented.

All presentations will be available on KalVista's website under 'Publications'.

KalVista Pharmaceuticals (NASDAQ: KALV) announced that the European Medicines Agency (EMA) has validated the submission of a Marketing Authorization Application (MAA) for sebetralstat, an oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema (HAE). If approved, sebetralstat would be the first oral, on-demand treatment for HAE in Europe. The MAA is supported by results from the KONFIDENT phase 3 clinical trial and ongoing KONFIDENT-S open label extension trial.

Key findings include:

• Sebetralstat met the primary endpoint in phase 3 trials
• Both 300 mg and 600 mg formulations achieved faster symptom relief than placebo
• Median time to beginning of symptom relief for laryngeal attacks was 1.3 hours
• KalVista submitted a New Drug Application (NDA) to the U.S. FDA in June 2024
• KONFIDENT-KID clinical trial initiated to evaluate sebetralstat in pediatric patients aged 2-11 years

KalVista Pharmaceuticals (NASDAQ: KALV) has granted inducement options to eleven newly-hired employees to purchase a total of 90,000 shares of KalVista common stock. The options, issued on August 1, 2024, have an exercise price of $13.83 per share, matching the closing price on the grant date. The vesting schedule includes 25% after one year, with the remainder vesting in equal monthly installments over three years, subject to continued employment. Each option has a 10-year term and falls under KalVista's Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).

KalVista Pharmaceuticals has submitted a New Drug Application (NDA) for sebetralstat, an oral treatment for hereditary angioedema (HAE) attacks, potentially launching in the first half of 2025. The phase 3 KONFIDENT trial data, published in The New England Journal of Medicine, supports the drug's efficacy. The company began a pediatric trial and plans additional regulatory submissions across Europe and Japan this year. Financially, KalVista reported no revenue for the fiscal year ending April 30, 2024. R&D expenses rose to $86.2 million, while G&A expenses increased to $54.3 million. The net loss widened to $126.6 million, or $(3.44) per share. Cash reserves grew to $210.4 million, primarily due to a stock offering in February 2024.

KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of inducement options to twelve newly-hired employees, allowing them to purchase a total of 84,000 shares of common stock as of July 1, 2024. The options were granted under Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $11.89 per share, matching the closing price on the grant date. These options vest over four years, with one-fourth vesting after one year and the remainder vesting monthly over the next three years, contingent on continued employment. Each option has a 10-year term and is governed by KalVista's Inducement Equity Incentive Plan and relevant option agreements.

KalVista Pharmaceuticals (NASDAQ: KALV) has launched the KONFIDENT-KID trial to evaluate sebetralstat, an oral plasma kallikrein inhibitor, for treating hereditary angioedema (HAE) attacks in children aged 2 to 11. The open-label trial will enroll 24 children across seven countries in North America, Europe, and Asia. Over one year, it will gather safety, pharmacokinetic, and efficacy data using a pediatric oral disintegrating tablet formulation of sebetralstat. If successful, sebetralstat could become the first oral on-demand therapy for this age group, addressing a significant unmet need, as the current option is an intravenous treatment.

KalVista Pharmaceuticals (NASDAQ: KALV) has submitted a New Drug Application (NDA) to the FDA for sebetralstat, an oral plasma kallikrein inhibitor intended for the on-demand treatment of hereditary angioedema (HAE) in patients aged 12 and older. The NDA is based on successful phase 3 trial results showing rapid symptom relief, with sebetralstat significantly outperforming placebo. If approved, sebetralstat would be the first oral on-demand HAE treatment. The FDA's review decision is expected in September 2024. KalVista also plans to submit marketing applications globally and initiate a pediatric trial in Q3 2024.